Who We Are
The Experimental Cancer Therapeutics Unit (ECRU) was set up with the purpose of academically enhancing support for early phase clinical trials. Its focus is on providing a single point of engagement for the conduct of Phase 0/1/2 trials. The unit is part of the Department of Medical Oncology and was initiated in 2009. The core team collaborates closely with other clinicians and scientists committed to preclinical and clinical development of new anticancer drugs. Our core interests cover all solid tumours and lymphomas.
At ECRU, we coordinate the aspects of modern drug development from target discovery and validation, xenograft drug screening, clinical pharmacology and biomarker correlative clinical trials. This includes the ability to do sequential tumor biopsies for biomarker development in certain trials.
Mission of ECRU:
Mission Statement: To define the future standards of personalized cancer care through innovative drug development
• To bring new and novel agents to the patient’s bedside and develop new therapeutic options for cancer patients through scientifically driven sponsored and investigator-initiated research.• To facilitate the efficient execution of biomarker correlative early phase clinical trials in cancer patients• To provide a training platform for translation research both nationally and regionally
Ongoing Phase 1 Trials
Please click here for the ongoing Phase 0/1/2 trials.
Preclinical/clinical support and capabilities on campus:
Quality Assurance and Trials Management:
As part of the Department of Medical Oncology, our core team of doctors are specialists within the department. These oncologists have tumour specific interests. They are aided by 20 Clinical Research Coordinators.
Key Staff of ECRU:
We have a variety of trials ongoing. For more information and to enquire about the availability of the trials, please email: firstname.lastname@example.org.
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Crescent, Singapore 169610 +65 6436 8000